Skip to main content
OpenTrials
Completed

NCT Number: NCT04896619

Cholesterol Effects of Kori-tofu Proteins

The study is a randomized, cross-over, double-blind, controlled trial in which participants with mildly elevated levels of cholesterol will receive two 4-week interventions (e.g. kori-tofu or control), with a wash-out period of 4 weeks in between. During the intervention periods, subjects will eat 3 slices of bread per day, representing a Kori-tofu dose of 34.5 grams or a matched reference. Fasting total and LDL cholesterol will be determined at the start and end of each of the two intervention periods.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wageningen University & Research

Wageningen, Gelderland, 6708 WG, Netherlands

About this study

There are several types of tofu, an example of a specific type of tofu is called Kori-tofu. Kori-tofu literally means frozen tofu. The production process of Kori-tofu leads to the formation of a higher high molecular weight fraction (HMF) content of the soy proteins. Several studies describe the effects of Kofi-tofu on health. In this study the aim is to investigate the effect of repetitive consumption of Kori-tofu on blood cholesterol levels and other lipid metabolism related measures, in research subjects with mildly elevated levels of cholesterol.

The primary objective is to assess the effect of repetitive consumption of Kori-tofu on blood total and LDL cholesterol levels. The secondary objective is to assess the effect of repetitive consumption of Kori-tofu on other markers of lipid metabolism, glucose metabolism and blood pressure.

The study is a randomized, cross-over, double-blind, controlled trial in which participants will receive two 4-week interventions (e.g. kori-tofu or control), with a wash-out period of 4 weeks in between. During the intervention periods, subjects will eat 3 slices of bread per day, representing a Kori-tofu dose of 34.5 grams or a matched reference (whey protein, soy oil and maltodextrin/cellulose). Research subjects will visit our research unit before and after each intervention period for a test day. During these test days fasting blood samples will be collected and blood pressure measurements will be performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 40-70 years;
  • BMI between 18.5-35 kg/m2;
  • Total cholesterol levels >5 mmol/L or LDL >3 mmol/L

Exclusion criteria

  • Use of medication/supplements/food items that may influence the study results, such as cholesterol lowering medication, Becel ProActiv (judged by our research physician);
  • Total cholesterol levels >7 mmol/L;
  • LDL cholesterol levels >5 mmol/L;
  • Reported slimming, medically prescribed or other extreme diets;
  • Reported weight loss or weight gain of >5 kg in the month prior to pre-study screening;
  • Not willing to give up blood donation during the study;
  • Current smokers;
  • Alcohol intake ≥4 glasses of alcoholic beverages per day;
  • Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported);
  • Abuse of soft and/or hard drugs;
  • Food allergies or intolerances for products that we use in the study;
  • Participation in another clinical trial at the same time; NL75320.081.20 CHOKO Version number: 4, April 2021 15 of 34
  • Being an employee of the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

Treatment and study plan

Kori tofu bread

Other

34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.

Whey protein bread

Other

Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread

Primary outcomes

  1. Change in total cholesterol levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  2. Change in LDL cholesterol levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

Secondary outcomes

  1. Change in HDL cholesterol levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  2. Change in triglycerides levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  3. Change in leptin levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  4. Change in adiponectin levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  5. Change in plasma insulin levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  6. Change in HbA1c levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  7. Change in fructosamine levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  8. Change in glucose levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  9. Change in systolic blood pressure levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

  10. Change in diastolic blood plessure levels

    Time frame: 0 weeks, 4 weeks, 8 weeks and 12 weeks

    under fasting conditions

Sponsors and collaborators

Lead sponsor

Wageningen University and Research

Other

Collaborators

  • Asahimatsu Foods

Registry information

Acronym: CHOKO

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 21, 2021
Registry last updated
Dec 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.